MedTrace Logo

XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer

NCT00215722 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2007-04-06

No results posted yet for this study

Summary

The first phase II trial with cetuximab and FOLFOX, as 1st line therapy for MCRC, presented at ASCO 2004, showed a 81% response rate, with no unexpected toxicities for the combination.

This study is aimed at establishing the efficacy and safety of the combination cetuximab/XELOX as first line therapy in patients with MCRC.

Conditions

  • Colorectal Carcinoma

Interventions

DRUG

Cetuximab

Sponsors & Collaborators

  • Grupo de Investigacao do Cancro Digestivo

    lead OTHER

Principal Investigators

  • Evaristo Sanches, MD · Grupo de Investigação do Cancro Digestivo

  • Sérgio Barroso, MD · Grupo de Investigação do Cancro Digestivo

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Completion
2008-07-31

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00215722 on ClinicalTrials.gov